Hematologic toxicity and double autografting of stem cells after myeloablative activities of yttrium-90-ibritumomab tiuxetan

J Clin Oncol. 2009 Mar 1;27(7):1145-6; author reply 1146. doi: 10.1200/JCO.2008.20.8769. Epub 2009 Jan 26.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Humans
  • Radioimmunotherapy* / adverse effects
  • Radioimmunotherapy* / economics
  • Stem Cell Transplantation / economics
  • Stem Cell Transplantation / methods*
  • Transplantation Conditioning* / adverse effects
  • Transplantation Conditioning* / economics

Substances

  • Antibodies, Monoclonal
  • ibritumomab tiuxetan